Ajanta Pharma (NSE:AJANTPHARM) Cyclically Adjusted Revenue per Share: ₹317.98 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AJANTPHARM Ajanta Pharma Ltd NSE:AJANTPHARM
95 GF Score
Price ₹3,481.70
GF Value ₹3,348.50
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ajanta Pharma Cyclically Adjusted Revenue per Share?

Ajanta Pharma NSE:AJANTPHARM -0.66% 95 Cyclically Adjusted Revenue per Share is ₹317.98 as of Jun. 2026. GuruFocus rates NSE:AJANTPHARM with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ajanta Pharma's adjusted revenue per share for the three months ended in Jun. 2026 was ₹129.992. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹317.98 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Ajanta Pharma's average Cyclically Adjusted Revenue Growth Rate was 13.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Ajanta Pharma was 10.70% per year. The lowest was 9.80% per year. And the median was 10.25% per year.

As of today (2026-09-03), Ajanta Pharma's current stock price is ₹3481.70. Ajanta Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹317.98. Ajanta Pharma's Cyclically Adjusted PS Ratio of today is 10.95.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ajanta Pharma was 13.22. The lowest was 5.23. And the median was 8.71.


Ajanta Pharma  (NSE:AJANTPHARM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ajanta Pharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3481.70/317.98
=10.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ajanta Pharma was 13.22. The lowest was 5.23. And the median was 8.71.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ajanta Pharma Cyclically Adjusted Revenue per Share Related Terms


Ajanta Pharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ajanta Pharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ajanta Pharma Cyclically Adjusted Revenue per Share Chart

Ajanta Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 204.67 224.87 243.40 271.01 305.12

Ajanta Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 280.08 289.85 296.86 305.12 317.98

NSE:AJANTPHARM vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ajanta Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ajanta Pharma's Cyclically Adjusted PS Ratio falls into.


NSE:AJANTPHARM
95GF Score
Ajanta Pharma Ltd NSE:AJANTPHARM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ajanta Pharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ajanta Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=129.992/167.3573*167.3573
=129.992

Current CPI (Jun. 2026) = 167.3573.

Ajanta Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 39.083 105.961 61.729
201612 40.351 105.196 64.195
201703 36.103 105.196 57.437
201706 35.837 107.109 55.995
201709 40.917 109.021 62.811
201712 44.479 109.404 68.040
201803 40.184 109.786 61.256
201806 38.706 111.317 58.192
201809 41.224 115.142 59.919
201812 36.740 115.142 53.401
201903 36.086 118.202 51.093
201906 46.764 120.880 64.744
201909 49.089 123.175 66.697
201912 49.731 126.235 65.931
202003 50.100 124.705 67.235
202006 51.040 127.000 67.259
202009 54.675 130.118 70.323
202012 57.679 130.889 73.749
202103 53.518 131.771 67.971
202106 57.644 134.084 71.948
202109 68.186 135.847 84.002
202112 64.532 138.161 78.169
202203 62.920 138.822 75.854
202206 74.225 142.347 87.266
202209 73.203 144.661 84.688
202212 75.857 145.763 87.095
202303 66.088 146.865 75.310
202306 81.097 150.280 90.313
202309 81.622 151.492 90.170
202312 87.715 152.924 95.994
202403 79.934 153.035 87.415
202406 90.981 155.789 97.737
202409 94.611 157.882 100.289
202412 91.491 158.323 96.712
202503 93.525 157.552 99.346
202506 104.226 159.755 109.186
202509 108.324 162.289 111.707
202512 110.029 163.281 112.776
202603 113.752 164.272 115.888
202606 129.992 167.357 129.992

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹317.98 mean?
Ajanta Pharma (NSE:AJANTPHARM) has a Cyclically Adjusted Revenue per Share of ₹317.98 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ajanta Pharma and its competitors.
Is Ajanta Pharma's Cyclically Adjusted Revenue per Share too high?
Ajanta Pharma's current Cyclically Adjusted Revenue per Share is ₹317.98. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Cyclically Adjusted Revenue per Share compare to ZTS?
Ajanta Pharma's Cyclically Adjusted Revenue per Share of ₹317.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ajanta Pharma and its competitors. Ajanta Pharma's current Cyclically Adjusted Revenue per Share is ₹317.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (NSE:AJANTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,481.70 — trading 4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹317.98. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ajanta Pharma (NSE:AJANTPHARM), the current Cyclically Adjusted Revenue per Share is ₹317.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ajanta Pharma (NSE:AJANTPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued. The current stock price of ₹3,481.70 is trading 4% above its estimated GF Value™ of ₹3,348.50. GuruFocus considers Ajanta Pharma to be Fairly Valued.

Key valuation signals for NSE:AJANTPHARM:

  • Cyclically Adjusted Revenue per Share: ₹317.98
  • GF Value™: ₹3,348.50 vs. price of ₹3,481.70 (4% above fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the NSE:AJANTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ajanta Pharma Business Description

Other Exchanges 532331:India
Address M Vasanji Road, Ajanta Tower, 54-A, Chakala, Andheri East, Mumbai, MH, IND, 400 093
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score

Get the complete analysis for NSE:AJANTPHARM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,481.70
Price
₹3,348.50
GF Value